High Court Refuses to Hear Case on Six-Month Wait for Biosimilar Launch

The U.S. Supreme Court has declined to hear a case on whether all biosimilar makers must give a six-month notice before bringing an FDA-approved product to market, even when disclosures were made earlier in the approval process.
Source: Generic Line